PRESS RELEASE: World-Leading Urology Body Selects Australian Early Prostate Cancer Treatment for Global Showcase

Melbourne, Australia | 3 February 2026

ImmunoPDT has been selected to present at the American Urological Association’s (AUA) 2026 Innovation Nexus Forum in Washington, DC on May 14, 2026. The selection features ImmunoPDT’s lead program, Immuno1 — an investigational, orally administered photodynamic therapy (PDT) agent developed for early-stage prostate cancer.

In Phase 1 outcomes presented by Founder, Dr Don Murphy, follow-up of 10–12 years was cited, with 0% incontinence and 0% erectile dysfunction. ImmunoPDT has secured TGA CTN approvals for Phase 1 and 2 trials. To date, more than A$40 million has been invested in the development of this technology.

———

Filling the gap between monitoring and invasive treatment

ImmunoPDT is being developed for the large group of men with early-stage prostate cancer who often face a difficult choice: active surveillance (“watch and wait”) or more invasive treatments that can impact long-term urinary and sexual function. There is no current pharmacologic option for low-to-intermediate-risk localised prostate cancer as an alternative to active surveillance or definitive local therapy. The program will target this clinical and commercial white space with its function-preserving early intervention as a first stage.

———

A targeted, local treatment designed to preserve quality of life

For many men with early prostate cancer, the challenge is achieving effective treatment while preserving urinary and sexual function. ImmunoPDT is being developed as a minimally invasive approach for prostate-confined disease. It is taken orally and designed to be taken up preferentially by tumour tissue. A controlled light source is then used to activate the treatment in the prostate. This “switch-on” step is intended to focus the effect where it is needed and limit activity elsewhere in the body. Early clinical data to date is consistent with the program’s function-preserving intent and locally targeted whole-of-prostate treatment design.

———

Progressing through Phase 2 with a clear pathway toward U.S. IND milestones

A Phase 2 trial in Australia will be ongoing. ImmunoPDT reports interim observations consistent with the Phase 1 safety profile and clinical activity signals in a subset of patients. The company states that its Phase 2 design aligns with U.S. FDA and EMA requirements for registration trials in those jurisdictions.

———

Selected for a showcase built to connect clinicians, investors and industry partners

The AUA Innovation Nexus Forum is designed to foster collaboration, spotlight high-potential startups, and deliver actionable insights for investors and strategic partners. For investors and industry stakeholders, the Showcase offers a first look at emerging technologies shaping the future of urologic care.

Mark Lawrence, ImmunoPDT Director, said: “Early prostate cancer forces a difficult trade-off between monitoring and treatments that can impact long-term function, and ImmunoPDT is being developed to offer a targeted, minimally invasive option.”

“It is a major achievement for the company to be a finalist in the biggest Urology Society’s Innovation Program, which brings together the clinicians, strategic partners and investors needed to help translate promising science into real-world patient benefit.”

———

Capital raise

ImmunoPDT is finalising a capital raise to support its next stage of clinical development, including U.S. IND pathway planning and a Phase 1b/2 study intended to support U.S. regulatory progression. The company will present ImmunoPDT at the 2026 AUA Innovation Nexus Forum on May 14, 2026, in Washington, DC, as part of a broader investor and partner engagement program. ImmunoPDT will meet with urology key opinion leaders, potential collaborators and stakeholders, and prospective investors and strategic partners ahead of and during the Forum. The outcome will advance ImmunoPDT’s clinical development and key regulatory and commercial milestones.

———

About ImmunoPDT

ImmunoPDT is an Australian clinical-stage company developing the ImmunoPDT photodynamic therapy platform (oral agent plus light-based instrument), led by its investigational agent Immuno1.

About Immuno1

Immuno1 is an investigational, orally administered photosensitiser intended for use with light activation to generate a local photochemical effect within the prostate treatment field. Immuno1 is protected by patents.

About the American Urological Association

Founded in 1902, the American Urological Association is a leading advocate for the specialty of urology with more than 24,000 members worldwide and a mission focused on advancing the highest standards of urologic care through education, research and health policy.

———

Media and investor enquiries

Investor enquiries
Mark Lawrence, Director
[email protected]
+61 411883231

Media enquiries
Ben Durrant, Investor & Stakeholder Relations
[email protected]
+61 400019395

———

Notes to editors

• Photodynamic therapy (PDT) is a treatment approach that uses a light-activated compound (a photosensitiser) and a specific light source to generate a local therapeutic effect at the treatment site.
• IND refers to an Investigational New Drug application filed with the U.S. Food and Drug Administration (FDA) to enable clinical trials in the United States.
• CTN refers to the Clinical Trial Notification pathway used in Australia for certain clinical trials (administered by the Therapeutic Goods Administration, TGA).
• “Early-stage” or “localised” prostate cancer generally refers to disease that is confined to the prostate and has not spread to distant organs; clinical definitions may vary by risk group and guideline.
• Clinical-stage programs are investigational. Statements about safety, efficacy, or clinical outcomes should be interpreted in the context of the study design, patient numbers, endpoints, and follow-up period.
• Any reference to “selection”, “showcase”, or “forum” should be interpreted as a presentation opportunity and does not constitute an endorsement of product safety or effectiveness by the hosting organisation.
• This media release may include forward-looking statements. Actual results may differ materially due to risks, uncertainties, and factors outside the company’s control.
• This communication is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in any jurisdiction.